GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolys BioPharma Inc (TSE:4588) » Definitions » EBITDA Margin %

Oncolys BioPharma (TSE:4588) EBITDA Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Oncolys BioPharma EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Oncolys BioPharma's EBITDA for the three months ended in Mar. 2024 was 円-362.15 Mil. Oncolys BioPharma's Revenue for the three months ended in Mar. 2024 was 円0.00 Mil. Therefore, Oncolys BioPharma's EBITDA margin for the quarter that ended in Mar. 2024 was 0.00%.


Oncolys BioPharma EBITDA Margin % Historical Data

The historical data trend for Oncolys BioPharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolys BioPharma EBITDA Margin % Chart

Oncolys BioPharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -69.14 -662.77 -249.19 -116.90 -3,061.15

Oncolys BioPharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -920.29 -1,938.17 - - -

Competitive Comparison of Oncolys BioPharma's EBITDA Margin %

For the Biotechnology subindustry, Oncolys BioPharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncolys BioPharma's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolys BioPharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Oncolys BioPharma's EBITDA Margin % falls into.



Oncolys BioPharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Oncolys BioPharma's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-1929.69/63.038
=-3,061.15 %

Oncolys BioPharma's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-362.152/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncolys BioPharma  (TSE:4588) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Oncolys BioPharma EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Oncolys BioPharma's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncolys BioPharma (TSE:4588) Business Description

Traded in Other Exchanges
N/A
Address
4-1-28 Toranomon, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
Oncolys BioPharma Inc develops pharmaceutical products. The company is engaged in research and development of oncolytic viruses, drugs for serious infectious diseases, molecular targeted anti-cancer drugs, and tumor diagnostic agents.

Oncolys BioPharma (TSE:4588) Headlines

No Headlines